Diagnosis and management of hepatitis C

Jeff T Wilkins, Mariam Akhtar, Eunice Gititu, Christine Jalluri, Jason Ramirez

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection, a major cause of chronic liver disease and cirrhosis, is predominantly transmitted by exposure to blood or body fluids. The infection progresses to a chronic state in 80% of patients, whereas the virus clears completely after the acute infection in 20% of patients. Screening for HCV with an anti-HCV antibody test is recommended for all adults at high risk of infection, and one-time screening is recommended in adults born between 1945 and 1965. If the anti-HCV antibody test result is positive, current infection should be confirmed with a qualitative HCV RNA test. In patients with confirmed HCV infection, quantitative HCV RNA testing and testing for HCV genotype is recommended. An assessment of the degree of liver fibrosis with liver biopsy or noninvasive testing is necessary to determine the urgency of treatment. Treatment of patients with chronic HCV infection should be considered based on genotype, extent of fibrosis or cirrhosis, prior treatment, comorbidities, and potential adverse effects. The goal of therapy is to reduce all-cause mortality and liver-associated complications. Although interferon-based regimens have been the mainstay of treatment for HCV infection, the U.S. Food and Drug Administration recently approved two combination-pill interferon-free treatments (ledipasvir plus sofosbuvir, and ombitasvir/paritaprevir/ritonavir plus dasabuvir) for chronic HCV genotype 1.

Original languageEnglish (US)
Pages (from-to)835-842
Number of pages8
JournalAmerican Family Physician
Volume91
Issue number12
StatePublished - 2015

Fingerprint

Hepatitis C
Hepacivirus
Virus Diseases
Hepatitis C Antibodies
Genotype
Chronic Hepatitis C
Infection
Liver Cirrhosis
Interferons
Fibrosis
Therapeutics
RNA
Ritonavir
Liver
Body Fluids
United States Food and Drug Administration
Comorbidity
Liver Diseases
Chronic Disease
Viruses

ASJC Scopus subject areas

  • Family Practice

Cite this

Wilkins, J. T., Akhtar, M., Gititu, E., Jalluri, C., & Ramirez, J. (2015). Diagnosis and management of hepatitis C. American Family Physician, 91(12), 835-842.

Diagnosis and management of hepatitis C. / Wilkins, Jeff T; Akhtar, Mariam; Gititu, Eunice; Jalluri, Christine; Ramirez, Jason.

In: American Family Physician, Vol. 91, No. 12, 2015, p. 835-842.

Research output: Contribution to journalArticle

Wilkins, JT, Akhtar, M, Gititu, E, Jalluri, C & Ramirez, J 2015, 'Diagnosis and management of hepatitis C', American Family Physician, vol. 91, no. 12, pp. 835-842.
Wilkins JT, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and management of hepatitis C. American Family Physician. 2015;91(12):835-842.
Wilkins, Jeff T ; Akhtar, Mariam ; Gititu, Eunice ; Jalluri, Christine ; Ramirez, Jason. / Diagnosis and management of hepatitis C. In: American Family Physician. 2015 ; Vol. 91, No. 12. pp. 835-842.
@article{046efce62bd24c08b680421d7ef7c327,
title = "Diagnosis and management of hepatitis C",
abstract = "Hepatitis C virus (HCV) infection, a major cause of chronic liver disease and cirrhosis, is predominantly transmitted by exposure to blood or body fluids. The infection progresses to a chronic state in 80{\%} of patients, whereas the virus clears completely after the acute infection in 20{\%} of patients. Screening for HCV with an anti-HCV antibody test is recommended for all adults at high risk of infection, and one-time screening is recommended in adults born between 1945 and 1965. If the anti-HCV antibody test result is positive, current infection should be confirmed with a qualitative HCV RNA test. In patients with confirmed HCV infection, quantitative HCV RNA testing and testing for HCV genotype is recommended. An assessment of the degree of liver fibrosis with liver biopsy or noninvasive testing is necessary to determine the urgency of treatment. Treatment of patients with chronic HCV infection should be considered based on genotype, extent of fibrosis or cirrhosis, prior treatment, comorbidities, and potential adverse effects. The goal of therapy is to reduce all-cause mortality and liver-associated complications. Although interferon-based regimens have been the mainstay of treatment for HCV infection, the U.S. Food and Drug Administration recently approved two combination-pill interferon-free treatments (ledipasvir plus sofosbuvir, and ombitasvir/paritaprevir/ritonavir plus dasabuvir) for chronic HCV genotype 1.",
author = "Wilkins, {Jeff T} and Mariam Akhtar and Eunice Gititu and Christine Jalluri and Jason Ramirez",
year = "2015",
language = "English (US)",
volume = "91",
pages = "835--842",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "12",

}

TY - JOUR

T1 - Diagnosis and management of hepatitis C

AU - Wilkins, Jeff T

AU - Akhtar, Mariam

AU - Gititu, Eunice

AU - Jalluri, Christine

AU - Ramirez, Jason

PY - 2015

Y1 - 2015

N2 - Hepatitis C virus (HCV) infection, a major cause of chronic liver disease and cirrhosis, is predominantly transmitted by exposure to blood or body fluids. The infection progresses to a chronic state in 80% of patients, whereas the virus clears completely after the acute infection in 20% of patients. Screening for HCV with an anti-HCV antibody test is recommended for all adults at high risk of infection, and one-time screening is recommended in adults born between 1945 and 1965. If the anti-HCV antibody test result is positive, current infection should be confirmed with a qualitative HCV RNA test. In patients with confirmed HCV infection, quantitative HCV RNA testing and testing for HCV genotype is recommended. An assessment of the degree of liver fibrosis with liver biopsy or noninvasive testing is necessary to determine the urgency of treatment. Treatment of patients with chronic HCV infection should be considered based on genotype, extent of fibrosis or cirrhosis, prior treatment, comorbidities, and potential adverse effects. The goal of therapy is to reduce all-cause mortality and liver-associated complications. Although interferon-based regimens have been the mainstay of treatment for HCV infection, the U.S. Food and Drug Administration recently approved two combination-pill interferon-free treatments (ledipasvir plus sofosbuvir, and ombitasvir/paritaprevir/ritonavir plus dasabuvir) for chronic HCV genotype 1.

AB - Hepatitis C virus (HCV) infection, a major cause of chronic liver disease and cirrhosis, is predominantly transmitted by exposure to blood or body fluids. The infection progresses to a chronic state in 80% of patients, whereas the virus clears completely after the acute infection in 20% of patients. Screening for HCV with an anti-HCV antibody test is recommended for all adults at high risk of infection, and one-time screening is recommended in adults born between 1945 and 1965. If the anti-HCV antibody test result is positive, current infection should be confirmed with a qualitative HCV RNA test. In patients with confirmed HCV infection, quantitative HCV RNA testing and testing for HCV genotype is recommended. An assessment of the degree of liver fibrosis with liver biopsy or noninvasive testing is necessary to determine the urgency of treatment. Treatment of patients with chronic HCV infection should be considered based on genotype, extent of fibrosis or cirrhosis, prior treatment, comorbidities, and potential adverse effects. The goal of therapy is to reduce all-cause mortality and liver-associated complications. Although interferon-based regimens have been the mainstay of treatment for HCV infection, the U.S. Food and Drug Administration recently approved two combination-pill interferon-free treatments (ledipasvir plus sofosbuvir, and ombitasvir/paritaprevir/ritonavir plus dasabuvir) for chronic HCV genotype 1.

UR - http://www.scopus.com/inward/record.url?scp=84930982289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930982289&partnerID=8YFLogxK

M3 - Article

C2 - 26131943

AN - SCOPUS:84930982289

VL - 91

SP - 835

EP - 842

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 12

ER -